# Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

> **NCT07498517** · PHASE2 · NOT_YET_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 90 (estimated)

## Conditions studied

- Thrombosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Gruticibart
- **PROCEDURE:** Ultrasound
- **PROCEDURE:** Biopspecimen collection

## Key facts

- **NCT ID:** NCT07498517
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2029-02-02
- **Final completion:** 2029-10-02
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498517, "Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07498517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*